Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Kintor COVID-19 Candidate to Target Higher Risk Patients

publication date: Dec 27, 2021

Suzhou Kintor Pharma reported it will seek permission to enroll higher risk COVID-19 patients in its mainly US Phase III trial of proxalutamide. In an interim analysis, the candidate did not meet specified efficacy rates in non-hospitalized COVID-19 patients with mild disease. Kintor now wants to enroll only hospitalized COVID-19 patients with multiple comorbidities and/or patients with no COVID-19 vaccination history. So far, the candidate has been well-tolerated in the 348 patients enrolled with mild-to-moderate COVID-19 symptoms. More details....

Stock Symbol: (HK: 9939)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio Event
Singapore and Digital
April 26-27, 2023
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China